MX2016014429A - Inhibidores del transportador de 2 de monoamina vesicular (vmat2) para el tratamiento de trastornos del movimiento hipercineticos. - Google Patents
Inhibidores del transportador de 2 de monoamina vesicular (vmat2) para el tratamiento de trastornos del movimiento hipercineticos.Info
- Publication number
- MX2016014429A MX2016014429A MX2016014429A MX2016014429A MX2016014429A MX 2016014429 A MX2016014429 A MX 2016014429A MX 2016014429 A MX2016014429 A MX 2016014429A MX 2016014429 A MX2016014429 A MX 2016014429A MX 2016014429 A MX2016014429 A MX 2016014429A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- movement disorders
- hyperkinetic movement
- vmat2 inhibitors
- vmat2
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 208000000269 Hyperkinesis Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 230000001660 hyperkinetic effect Effects 0.000 abstract 1
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Se describen métodos para tratar enfermedades y trastornos hipercinéticos, tal como discinesia tardía. En una cierta modalidad, el inhibidor VMAT2 potente (+)a-3-isobutil-9,10-dimetox i-1,3,4,6,7,11b-hexahidro-2H-pirido [2,1-a] isoquinolin-2-ol ((+)a-HTBZ) se usa en los métodos descritos en la presente para tratar a un sujeto en necesidad del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461989240P | 2014-05-06 | 2014-05-06 | |
| PCT/US2015/029519 WO2015171802A1 (en) | 2014-05-06 | 2015-05-06 | Vmat2 inhibitors for the treatment of hyperkinetic movement disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016014429A true MX2016014429A (es) | 2017-04-06 |
| MX387625B MX387625B (es) | 2025-03-18 |
Family
ID=53264772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016014429A MX387625B (es) | 2014-05-06 | 2015-05-06 | Inhibidores del transportador de 2 de monoamina vesicular (vmat2) para el tratamiento de trastornos del movimiento hipercineticos. |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US20170071932A1 (es) |
| EP (3) | EP3139925B1 (es) |
| JP (4) | JP6635945B2 (es) |
| KR (5) | KR20250029267A (es) |
| CN (3) | CN106456629A (es) |
| AU (1) | AU2015256012B2 (es) |
| CA (1) | CA2947736C (es) |
| CY (1) | CY1125058T1 (es) |
| DK (2) | DK3936130T3 (es) |
| ES (2) | ES2976207T3 (es) |
| FI (1) | FI3936130T3 (es) |
| HR (2) | HRP20220025T1 (es) |
| HU (2) | HUE057839T2 (es) |
| IL (1) | IL248745B (es) |
| LT (2) | LT3139925T (es) |
| MX (1) | MX387625B (es) |
| NZ (1) | NZ725826A (es) |
| PL (2) | PL3936130T3 (es) |
| PT (2) | PT3139925T (es) |
| RS (2) | RS65359B1 (es) |
| RU (1) | RU2753740C2 (es) |
| SI (2) | SI3936130T1 (es) |
| SM (2) | SMT202400199T1 (es) |
| WO (1) | WO2015171802A1 (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE065406T2 (hu) * | 2015-10-30 | 2024-05-28 | Neurocrine Biosciences Inc | Valbenazin-dihidroklorid sók és polimorfjaik |
| SI3394057T1 (sl) | 2015-12-23 | 2022-06-30 | Neurocrine Biosciences, Inc. | Sintetičen postopek za pripravo (S)-(2R,3R,11bR)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1H- pirido(2,1,-a)izokinolin-2-il 2-amino-3-metilbutanoat di(4-metilbenzensulfonata) |
| EP3473623B1 (en) * | 2016-06-29 | 2020-07-15 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystal forms of nbi-98854, preparation method therefor and use thereof |
| JP2020500875A (ja) * | 2016-12-02 | 2020-01-16 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用 |
| WO2018130345A1 (en) | 2017-01-10 | 2018-07-19 | Sandoz Ag | Crystalline valbenazine free base |
| CA3051834C (en) | 2017-01-27 | 2024-05-28 | Neurocrine Bioscienes, Inc. | Methods for the administration of certain vmat2 inhibitors |
| JP2020508337A (ja) | 2017-02-27 | 2020-03-19 | サンド・アクチエンゲゼルシヤフト | バルベナジン塩の結晶形態 |
| WO2018164996A1 (en) * | 2017-03-06 | 2018-09-13 | Neurocrine Biosciences, Inc. | Dosing regimen for valbenazine |
| GB201705305D0 (en) * | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| US20180280374A1 (en) * | 2017-04-01 | 2018-10-04 | Adeptio Pharmaceuticals Limited | Pharmaceutical compositions |
| GB201705304D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705303D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705302D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705306D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| JP7250692B2 (ja) * | 2017-04-01 | 2023-04-03 | アデプティオ ファーマシューティカルズ リミテッド | 運動障害の治療における使用のためのジヒドロテトラベナジン |
| US20190111035A1 (en) * | 2017-04-01 | 2019-04-18 | Adeptio Pharmaceuticals Limited | Pharmaceutical compositions |
| US20200179352A1 (en) * | 2017-04-26 | 2020-06-11 | Neurocrine Biosciences, Inc. | Use of valbenazine for treating levodopa-induced dyskinesia |
| IL273300B2 (en) | 2017-09-21 | 2024-06-01 | Neurocrine Biosciences Inc | High dosage valbenazine formulation and compositions, methods, and kits related thereto |
| KR20200066661A (ko) | 2017-10-10 | 2020-06-10 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| KR20250070134A (ko) | 2017-10-10 | 2025-05-20 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| US11306082B2 (en) * | 2017-11-08 | 2022-04-19 | Foresee Pharmaceuticals Co., Ltd. | Esters of dihydrotetrabenazine |
| CA3086611C (en) | 2017-12-26 | 2023-07-25 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | A crystalline form of valbenazine ditosylate, processes for preparation thereof and use thereof |
| MX2020011269A (es) | 2018-04-25 | 2020-12-11 | Shinkei Therapeutics Llc | Dispositivo de administración transdérmica de tetrabenazina. |
| GB201808464D0 (en) | 2018-05-23 | 2018-07-11 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compounds for use in treating huntington's disease |
| CN112638387A (zh) | 2018-06-14 | 2021-04-09 | 纽罗克里生物科学有限公司 | Vmat2抑制剂化合物、组合物和与其相关的方法 |
| MA53239A (fr) | 2018-08-15 | 2022-05-04 | Neurocrine Biosciences Inc | Procédés d'administration de certains inhibiteurs de vmat2 |
| WO2020070236A1 (en) | 2018-10-04 | 2020-04-09 | Adeptio Pharmaceuticals Limited | (+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders |
| EP3965764A1 (en) * | 2019-05-09 | 2022-03-16 | Neurocrine Biosciences, Inc. | Methods for the administration of certain vmat2 inhibitors |
| US10940141B1 (en) | 2019-08-23 | 2021-03-09 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008058261A1 (en) * | 2006-11-08 | 2008-05-15 | Neurocrine Biosciences, Inc. | Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto |
| JP2010509336A (ja) * | 2006-11-09 | 2010-03-25 | ニューヨーク ユニバーシティ | サンドイッチ材料の製造方法、ガラス／セラミック／ガラス複合構造物、ガラス／セラミック／ガラス、医科あるいは歯科補綴、およびガラス／ジルコニア／ガラスサンドイッチ材料 |
| WO2011019956A2 (en) * | 2009-08-12 | 2011-02-17 | Biovail Laboratories International (Barbados) S.R.L. | Pharmaceutical compositions |
| US20110053866A1 (en) * | 2008-08-12 | 2011-03-03 | Biovail Laboratories International (Barbados) S.R.L. | Pharmaceutical compositions |
| GB2462611A (en) | 2008-08-12 | 2010-02-17 | Cambridge Lab | Pharmaceutical composition comprising tetrabenazine |
| NZ591615A (en) | 2008-09-18 | 2012-07-27 | Auspex Pharmaceuticals Inc | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| JP2013527237A (ja) * | 2010-06-01 | 2013-06-27 | オースペックス・ファーマシューティカルズ・インコーポレイテッド | ベンゾキノロン系ｖｍａｔ２阻害剤 |
| CA2883641C (en) * | 2012-09-18 | 2021-09-14 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| MX378664B (es) * | 2014-02-07 | 2025-03-10 | Neurocrine Biosciences Inc | Composiciones farmaceuticas que comprenden un farmaco antipsicotico y un inhibidor de la isoforma 2 del transportador de monomina vesicular (vmat2) y sus usos. |
-
2015
- 2015-05-06 DK DK21178882.3T patent/DK3936130T3/da active
- 2015-05-06 SI SI201532006T patent/SI3936130T1/sl unknown
- 2015-05-06 EP EP15724438.5A patent/EP3139925B1/en active Active
- 2015-05-06 KR KR1020257005033A patent/KR20250029267A/ko active Pending
- 2015-05-06 WO PCT/US2015/029519 patent/WO2015171802A1/en active Application Filing
- 2015-05-06 HU HUE15724438A patent/HUE057839T2/hu unknown
- 2015-05-06 RS RS20240380A patent/RS65359B1/sr unknown
- 2015-05-06 SM SM20240199T patent/SMT202400199T1/it unknown
- 2015-05-06 ES ES21178882T patent/ES2976207T3/es active Active
- 2015-05-06 CN CN201580023821.XA patent/CN106456629A/zh active Pending
- 2015-05-06 KR KR1020247001490A patent/KR20240011255A/ko not_active Ceased
- 2015-05-06 FI FIEP21178882.3T patent/FI3936130T3/fi active
- 2015-05-06 CN CN202011483135.XA patent/CN112741835A/zh active Pending
- 2015-05-06 KR KR1020207032879A patent/KR20200133003A/ko not_active Ceased
- 2015-05-06 LT LTEPPCT/US2015/029519T patent/LT3139925T/lt unknown
- 2015-05-06 EP EP21178882.3A patent/EP3936130B1/en active Active
- 2015-05-06 HR HRP20220025TT patent/HRP20220025T1/hr unknown
- 2015-05-06 EP EP24157482.1A patent/EP4389227A3/en active Pending
- 2015-05-06 HR HRP20240459TT patent/HRP20240459T1/hr unknown
- 2015-05-06 IL IL248745A patent/IL248745B/en unknown
- 2015-05-06 SI SI201531799T patent/SI3139925T1/sl unknown
- 2015-05-06 NZ NZ725826A patent/NZ725826A/en unknown
- 2015-05-06 DK DK15724438.5T patent/DK3139925T3/da active
- 2015-05-06 RU RU2016147523A patent/RU2753740C2/ru active
- 2015-05-06 PL PL21178882.3T patent/PL3936130T3/pl unknown
- 2015-05-06 SM SM20220193T patent/SMT202200193T1/it unknown
- 2015-05-06 ES ES15724438T patent/ES2904526T3/es active Active
- 2015-05-06 AU AU2015256012A patent/AU2015256012B2/en active Active
- 2015-05-06 RS RS20220008A patent/RS62782B1/sr unknown
- 2015-05-06 US US15/309,108 patent/US20170071932A1/en not_active Abandoned
- 2015-05-06 PT PT157244385T patent/PT3139925T/pt unknown
- 2015-05-06 HU HUE21178882A patent/HUE066361T2/hu unknown
- 2015-05-06 MX MX2016014429A patent/MX387625B/es unknown
- 2015-05-06 LT LTEP21178882.3T patent/LT3936130T/lt unknown
- 2015-05-06 KR KR1020227034399A patent/KR20220140647A/ko not_active Ceased
- 2015-05-06 PL PL15724438T patent/PL3139925T3/pl unknown
- 2015-05-06 CN CN202011483141.5A patent/CN112741836A/zh active Pending
- 2015-05-06 JP JP2016566238A patent/JP6635945B2/ja active Active
- 2015-05-06 KR KR1020167033765A patent/KR20160147044A/ko not_active Ceased
- 2015-05-06 CA CA2947736A patent/CA2947736C/en active Active
- 2015-05-06 PT PT211788823T patent/PT3936130T/pt unknown
-
2019
- 2019-10-02 JP JP2019181949A patent/JP2019218407A/ja not_active Withdrawn
- 2019-12-03 US US16/701,339 patent/US20200101063A1/en not_active Abandoned
-
2020
- 2020-09-15 US US17/021,362 patent/US20210196702A1/en not_active Abandoned
-
2021
- 2021-09-22 JP JP2021153918A patent/JP2021191799A/ja not_active Withdrawn
-
2022
- 2022-02-07 CY CY20221100104T patent/CY1125058T1/el unknown
-
2024
- 2024-07-29 JP JP2024122223A patent/JP2024153782A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016014429A (es) | Inhibidores del transportador de 2 de monoamina vesicular (vmat2) para el tratamiento de trastornos del movimiento hipercineticos. | |
| FR21C1048I2 (fr) | Pyrazoles substitués par un trifluoromethyle en tant qu`inhibiteurs de la kallicréine plasmatique humaine | |
| MX2023007841A (es) | Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer. | |
| CL2018003597A1 (es) | Pirimidin-2-ilamino-1h-pirazoles como inhibidores delrrk2 para el uso en el tratamiento de trastornos neurodegenerativos. | |
| CL2018003123A1 (es) | Terapia de combinación para el tratamiento del cáncer | |
| CL2016002027A1 (es) | Ciclopropilamina como inhibidor de la lsd1 | |
| MX2016013457A (es) | Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo. | |
| CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| MX394062B (es) | Métodos para el tratamiento del cáncer ovárico. | |
| NI201600051A (es) | Combinaciones de inhibidores de histona desacetilasa y farmacos inmunomoduladores | |
| MX381046B (es) | Anticuerpos anti-csf1r e inhibidores de pd-1/pd-l1, y usos de los mismos para el tratamiento de cáncer remisión a las solicitudes relacionadas. | |
| CL2018001226A1 (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer | |
| MX374633B (es) | Combinaciones terapeuticas para usarse en el tratamiento de tumores. | |
| EA201691594A1 (ru) | Циклопропиламины в качестве ингибиторов lsd1 | |
| ES2764110T8 (es) | Conjugado anticuerpo-fármaco y su utilización para el tratamiento del cáncer | |
| MX2016013950A (es) | Metodo para producir l-aminoacidos utilizando una bacteria alcalifilica. | |
| ES2727103T8 (es) | Conjugado anticuerpo-fármaco para IGF-1R y su utilización para el tratamiento del cáncer | |
| DK3229840T5 (da) | 3,5-dihydroxy-4-isopropyl-trans-stilben til anvendelse i topisk behandling af akne | |
| MX395231B (es) | Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de hígado graso, y uso de los mismos. | |
| CL2016001937A1 (es) | Compuestos de benzopirano funcionalizados y uso de los mismos | |
| UY36286A (es) | Tratamientos médicos basados en anamorelina | |
| DOP2016000297A (es) | Composiciones farmacéuticas útiles para tratar enfermedades infecciosas | |
| UY36070A (es) | Triterpenoides con actividad inhibidora de la maduración de hiv | |
| CO2017000950A2 (es) | Compuestos que comprenden oligonucleótidos modificados dirigidos a mir-103 y/o mir-107 para trastornos metabólicos | |
| MX2020009709A (es) | Composiciones farmaceuticas que comprenden acido dihomo-gamma-linolenico (dgla) y uso de las mismas. |